Here are the 10-K annual reports from ZYVERSA THERAPEUTICS INC (ZVSA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ZVSA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZVSA filings page.
ZyVersa Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing drugs for chronic renal and inflammatory diseases. Its two main platforms are VAR 200, a cholesterol efflux mediator for focal segmental glomerulosclerosis and other glomerular diseases, and IC 100, an inflammasome ASC inhibitor targeting cardiometabolic and other inflammatory conditions.
The company plans a Phase 2a basket trial of VAR 200 in FSGS and Alport syndrome patients in Q2-2026 and a planned IND for IC 100 in Q4-2026, followed by a Phase 1 trial in overweight subjects at cardiometabolic risk. ZyVersa relies on exclusive worldwide licenses from L&F Research and InflamaCORE, which include milestone and royalty obligations.
As of June 30, 2025, aggregate market value of common stock held by non-affiliates was about $3.3 million, based on a $0.68 Nasdaq closing price, and 8,095,921 common shares were outstanding as of March 25, 2026. In 2025, the company spent $1.1 million on research and development and recorded an $18.6 million impairment of in-process R&D, reflecting concerns about recoverability of its intangible asset.